South Korea secures enough COVID-19 vaccine doses for 44 million citizens
December 8, 2020Manufacturing and Production, Sales and Marketing COVID-19, Vaccine, south korea
The South Korean Government has announced plans to secure enough COVID-19 vaccine doses to inoculate 44 million of its citizens, …
China approves Takeda’s Takhzyro to prevent hereditary angioedema attacks in patients over 12
December 8, 2020Manufacturing and Production, Sales and Marketing China, Takeda
China’s National Medical Products Administration (NMPA) has given approval in the country for Takeda’s Takhzyro (lanadelumab), in a subcutaneous injection …
Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma
December 7, 2020Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis
Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising …
EMA receives filing for Janssen’s twice-yearly schizophrenia jab
December 7, 2020Sales and Marketing EMA, Janssen, schizophrenia
The European Medicines Agency (EMA) has received Janssen’s Marketing Authorisation Extension for paliperidone palmitate six-monthly (PP6M), an injectable therapy administered …
Jakafi outperforms best available therapy in steroid-refractory/dependent chronic graft-versus-host disease
December 7, 2020Research and Development, Sales and Marketing Incyte, Jakafi, Novartis
The first Phase 3 findings have been revealed for Jakafi (ruxolitinib) in the treatment of steroid-refractory or steroid-dependent chronic graft-versus-host disease …
Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia
December 7, 2020Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica
Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …
FDA approves Novo Nordisk’s Saxenda for adolescent obesity
December 7, 2020Sales and Marketing FDA, Novo Nordisk, saxenda
The FDA has awarded US approval to Novo Nordisk’s Saxenda (liraglutide) 3mg injection to treat obesity in patients between the …
Top Ten most popular articles on Pharmafile.com this week
December 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Dupixent, EMA, UK, Vaccine, top ten
As the year winds to a close, excitement is rising around the efficacy and availability of COVID-19 vaccines around the …
New research links metformin to decreased mortality risk in female patients hospitalised with COVID-19
December 4, 2020Medical Communications, Research and Development COVID-19, Vaccine, metformin
Researchers from the University of Minnesota Medical School (UMMS) and UnitedHealth Group have uncovered potential benefit of metformin, a generic …
IBM uncovers “precision phishing campaign” targeting global COVID-19 vaccine cold chain supply
December 4, 2020Manufacturing and Production, Medical Communications, Research and Development COVID-19, Vaccine, ibm
US tech firm IBM has reported that it has identified attempts by unknown parties to hack and disrupt elements of …
FDA approves BioCryst’s Orladeyo for reducing hereditary angioedema attacks
December 4, 2020Medical Communications, Sales and Marketing BioCryst, FDA, Orladeyo
BioCryst has scored FDA for its therapy Orladeyo (berotralstat) for reducing or preventing hereditary angioedema (HAE) attacks in patients over …
MSD cashes in on Moderna investment as FDA mulls COVID-19 vaccine approval
December 4, 2020Medical Communications, Sales and Marketing MSD, Moderna
Moderna has wrestled its way to the forefront of the industry amidst the COVID-19 pandemic, becoming one of its most …
Jazz and PharmaMar’s Zepzelca combo misses main goal in small cell lung cancer sub-population
December 3, 2020Research and Development PharmaMar, jazz pharma, trial failure
Jazz Pharma and PharmaMar have revealed that their jointly-developed therapy Zepzelca (lurbinectedin), when combined with doxorubicin, fell short of its …
Neurogene secures EMA orphan designation for gene therapy in rare, inherited aspartylglucosaminuria
December 3, 2020Sales and Marketing EMA, Neurogene, aspartylglucosaminuria
The European Medicines Agency (EMA) has bestowed Orphan Drug Designation (ODD) to Neurogene’s adeno-associated virus vector (AAV) gene therapy in …
Janssen scoops up rights to Hemera’s gene therapy for retinal geographic atrophy
December 3, 2020Sales and Marketing Hemera Biosciences, Janssen, Retina, geographic atrophy
Janssen is set to acquire the rights to Hemera Biosciences’ intravitreal gene therapy injection HMR59, the company has announced, to …
Drug-free nasal spray could prevent COVID-19 infection, promising data show
December 3, 2020Research and Development COVID-19, Nasal Spray, auris medical
Auris Medical has revealed promising new in vitro data for AM-301, its drug-free nasal spray, showing that the product could …
Roche secures emergency FDA approval for COVID-19 antibody test
December 3, 2020Sales and Marketing COVID-19, FDA, Roche
The FDA has awarded Emergency Use Authorization to Roche’s COVID-19 test to allow users in the US to analyse the …
Pharmafile.com’s weekly COVID-19 news round-up
December 2, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Image credit: CDC, Top 5, Vaccine
EMA receives Pfizer and BioNTech’s filing for conditional approval of COVID-19 vaccine in Europe – Published on 01/12/20
FDA greenlights Gavreto for advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer in over-12s
December 2, 2020Research and Development, Sales and Marketing FDA, Gavreto, Roche
The FDA has awarded accelerated approval to Roche and Blueprint Medicines’ Gavreto (pralsetinib) for the treatment of advanced or metastatic …
European approval for Janssen’s Tremfya in active psoriatic arthritis, either alone or in combo
December 2, 2020Research and Development, Sales and Marketing Europe, Janssen, Tremfya
The European Commission has authorised Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) in the treatment of active psoriatic arthritis (PsA), either …
Latest content
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
